{
    "clinical_study": {
        "@rank": "67325", 
        "acronym": "POSTAGE", 
        "arm_group": {
            "arm_group_label": "Observational (medical chart review)", 
            "description": "Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56."
        }, 
        "brief_summary": {
            "textblock": "This research trial studies medical chart review in determining outcomes of second-line\n      therapy in patients with acute graft-versus-host disease previously treated with\n      extracorporeal photopheresis or other systemic therapies. Gathering information about\n      second-line therapy in patients with acute graft-versus-host disease may help doctors learn\n      more about the disease and find better treatment."
        }, 
        "brief_title": "Medical Chart Review in Determining Outcomes of Second-Line Therapy in Patients With Acute Graft-versus-host Disease Previously Treated With Extracorporeal Photopheresis or Other Systemic Therapies", 
        "condition": "Graft Versus Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine 6-month freedom from treatment failure for second-line therapy for acute\n      graft versus host disease (aGVHD).\n\n      II. To show that extracorporeal photopheresis (ECP) is associated with a superior 6 month\n      (m) freedom from treatment failure (FFTF) as compared to other treatment modalities for\n      second line therapy for aGVHD.\n\n      III. To describe health care burden in patients receiving second line therapy for acute\n      GVHD.\n\n      IV. Quality of life measurement using Functional Assessment of Cancer Therapy-Bone Marrow\n      Transplant (FACT-BMT) in patients receiving second line therapy for aGVHD.\n\n      OUTLINE:\n\n      Study data are collected and managed using Research Electronic Data Capture (REDCap) tools\n      at baseline and on days 5, 28, and 56.\n\n      After completion of study, patients are followed up at 6 months, and 1 and 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Enrollment on study is within 5 days (including weekends) of starting second-line\n             therapy\n\n          -  aGVHD grade 2 or higher at time of enrollment; patients with late acute and recurrent\n             aGVHD are permitted\n\n          -  Donor lymphocyte induced aGVHD is permitted ONLY IF donor lymphocyte infusion given\n             for mixed chimerism and not for progression of disease and meeting all other\n             inclusion and exclusion criteria will be eligible\n\n          -  Corticosteroid refractory or corticosteroid dependent aGVHD\n\n               -  Corticosteroid refractory aGVHD is defined as worsening of aGVHD after 3 days of\n                  systemic corticosteroids (minimum dose of 1 mg/kg), or no improvement after 7\n                  days of systemic corticosteroids (minimum dose of 1 mg/kg)\n\n               -  Corticosteroid dependent aGVHD is defined as recurrence of aGVHD (grade 2 or\n                  higher) during corticosteroid taper and prior to reaching 50% of initial\n                  starting dose of corticosteroids\n\n          -  Informed consent form\n\n        Exclusion Criteria:\n\n          -  Has received corticosteroids at 2 mg/kg or higher for 3 weeks or longer as part of\n             first-line therapy for aGVHD\n\n          -  Has received systemic therapy other than corticosteroids for treatment of aGVHD as\n             part of first-line therapy for acute GVHD; simultaneous uses of topical or enteric\n             corticosteroids or psoralen plus ultraviolet A (PUVA) for first-line are permitted\n\n          -  aGVHD after second hematopoietic cell transplantation (HCT) is excluded\n\n          -  Karnofsky performance status =< 50%\n\n          -  Requiring mechanical ventilation or renal replacement therapy at the time of\n             enrollment\n\n          -  Histologic or flow-cytometric evidence of relapse or progression of underlying\n             disease; molecular or cytogenetic presence of disease is permitted; mixed chimerism\n             is permitted\n\n          -  Current or prior diagnosis of chronic GVHD (classic or overlap) as defined by\n             National Institutes of Health (NIH) consensus criteria\n\n          -  Donor lymphocyte infusion (DLI)-induced aGVHD when DLI was given for progression of\n             the underlying disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This study targets patients with acute graft-versus-host disease previously treated with\n        extracorporeal photopheresis or other systemic therapies. Patients can be enrolled by all\n        participating locations."
            }
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151539", 
            "org_study_id": "VICC BMT 1401", 
            "secondary_id": [
                "NCI-2014-01026", 
                "VICC BMT 1401", 
                "P30CA068485"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Observational (medical chart review)", 
                "description": "Ancillary studies", 
                "intervention_name": "medical chart review", 
                "intervention_type": "Other", 
                "other_name": "chart review"
            }, 
            {
                "arm_group_label": "Observational (medical chart review)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Other", 
                "other_name": "quality of life assessment"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "khera.nandita@mayo.edu", 
                    "last_name": "Nandita Khera", 
                    "phone": "480-342-3047"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Mayo Clinic in Arizona"
                }, 
                "investigator": {
                    "last_name": "Nandita Khera", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sabhyankar@kumc.edu", 
                    "last_name": "Sunil H. Abhyankar", 
                    "phone": "913-588-6029"
                }, 
                "facility": {
                    "address": {
                        "city": "Westwood", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66205"
                    }, 
                    "name": "University of Kansas Hospital - Westwood Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Sunil H. Abhyankar", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Hashmi.Shahrukh@mayo.edu", 
                    "last_name": "Shahrukh K. Hashmi", 
                    "phone": "507-538-3270"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Shahrukh K. Hashmi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "madan.jagasia@vanderbilt.edu", 
                    "last_name": "Madan H. Jagasia", 
                    "phone": "615-936-8422"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Madan H. Jagasia", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Hildegard.greinix@meduniwien.ac.at", 
                    "last_name": "Hildegard Greinix", 
                    "phone": "43 1 40400 4457"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }, 
                    "name": "Medical University Vienna"
                }, 
                "investigator": {
                    "last_name": "Hildegard Greinix", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "daniel.wolff@ukr.de", 
                    "last_name": "Daniel Wolff", 
                    "phone": "0941-944-5531"
                }, 
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "zip": "93053"
                    }, 
                    "name": "Klinikum der Universit\u00e4t Regensburg"
                }, 
                "investigator": {
                    "last_name": "Daniel Wolff", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "emma.das-gupta@nhs.net", 
                    "last_name": "Emma Das-Gupta", 
                    "phone": "01159691169 Ext 54666"
                }, 
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG5 1PB"
                    }, 
                    "name": "Nottingham City Hospital"
                }, 
                "investigator": {
                    "last_name": "Emma Das-Gupta", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)", 
        "overall_contact": {
            "last_name": "Vanderbilt Cancer Center Clinical Trial Information Program", 
            "phone": "800-811-8480"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt-Ingram Cancer Center", 
            "last_name": "Madan Jagasia", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Rates of 6 m FFTF will be estimated by subtracting rates of total failures from 100%.", 
                "measure": "6-month freedom from treatment failure, defined as a patient being alive, without relapse of underlying disease, and without the addition of new systemic therapy for the treatment of aGVHD, within 6 months of starting second line therapy", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Cox regression models will be used to identify risk factors for failure.", 
                "measure": "Cumulative incidence estimates of relapse", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Cox regression models will be used to identify risk factors for failure.", 
                "measure": "Cumulative incidence estimates of non-relapse mortality", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Cox regression models will be used to identify risk factors for failure.", 
                "measure": "Treatment change as causes of failure during second line treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The incremental budget spend between the patients receiving treatment with ECP and patients receiving other modalities will be measured and economic methods will be used to calculate an incremental cost effectiveness ratio for relevant clinical end points. Health economic data relating to hospitalizations (length of stay in myelosuppressive unit, high-dependency unit [step-down unit], intensive care unit), high cost drugs, total parenteral nutrition and surgical procedures will also be collected allowing comparisons to be made between patients treated with ECP and other treatment options.", 
                "measure": "Health care burden in patients receiving second line therapy for acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Quality of life measured using FACT-BMT", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151539"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt-Ingram Cancer Center", 
            "investigator_full_name": "Madan Jagasia, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Vanderbilt-Ingram Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt-Ingram Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}